Peginterferon lambda-1a

Drug Profile

Peginterferon lambda-1a

Alternative Names: BMS-914143; PEG-IL-29 - ZymoGenetics; PEG-interferon lambda; PEG-interleukin-29 - ZymoGenetics; PEG-rIL-29 - ZymoGenetics

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer Bristol-Myers Squibb; Eiger BioPharmaceuticals, Inc.; ZymoGenetics
  • Class Antivirals; Interleukins
  • Mechanism of Action Interleukin 29 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis D
  • No development reported Multiple sclerosis
  • Discontinued Cancer; Hepatitis B; Hepatitis C

Most Recent Events

  • 12 May 2017 The US FDA approves IND application for Hepatitis D
  • 03 May 2017 Phase-II clinical trials in Hepatitis D in Israel, Pakistan (SC) prior to May 2017
  • 03 May 2017 Eiger BioPharmaceuticals files an IND application with the US FDA for Hepatitis D
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top